Accro Bioscience
China - SuzhouCRO (Contract Research)
Focus: Accro Bioscience is a Series B-stage CRO/biotech hybrid focused on small-molecule drug development in immunology, headquartered in Suzhou, China. The company operates at the intersection of contract research and proprietary pipeline development with early-stage clinical programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Total Funding
$12M
Open Jobs
0
About Accro Bioscience
AI assessmentNot HiringNo open roles listed right now. Follow Accro Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT07070674A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.
Phase 1Help build intelligence for Accro Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.